Expertise in
14
conditions

Dr. Benjamin Teply

Oncology
Fred & Pamela Buffett Cancer Center-Nebraska Medical Center
505 S 45th St, 
Omaha, NE 
Offers Telehealth
Expertise in
14
conditions
Fred & Pamela Buffett Cancer Center-Nebraska Medical Center
505 S 45th St, 
Omaha, NE 

Overview

Benjamin Teply is an Oncologist in Omaha, Nebraska. Dr. Teply is highly rated in 14 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, WT1-Related Wilms Tumor Syndromes, Hormone Replacement Therapy (HRT), and Tissue Biopsy.

His clinical research consists of co-authoring 48 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Student in an Organized Health Care Education/Training Program in MI

Hospital Affiliations

Bellevue Medical Center, LLC
The Nebraska Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Great Plains Medicare Advantage
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 10 Less Insurance Carriers -

Locations

Fred & Pamela Buffett Cancer Center-Nebraska Medical Center
505 S 45th St, Omaha, NE 68198
Other Locations
Office
515 S 48th St, Omaha, NE 68198

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2025
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Other
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

48 Total Publications

Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.
Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: November 10, 2025
Similar Doctors
Expertise in
42
conditions
Dr. Nicole Shonka
Oncology
Expertise in
42
conditions
Dr. Nicole Shonka
Oncology

Fred & Pamela Buffett Cancer Center-Nebraska Medical Center

505 S 45th St, 
Omaha, NE 
 (0.2 miles away)
402-559-5600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nicole Shonka is an Oncologist in Omaha, Nebraska. Dr. Shonka is highly rated in 42 conditions, according to our data. Her top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor.

Expertise in
25
conditions
Dr. Robert Bociek
Oncology
Expertise in
25
conditions
Dr. Robert Bociek
Oncology

Fred & Pamela Buffett Cancer Center-Nebraska Medical Center

505 S 45th St, 
Omaha, NE 
 (0.2 miles away)
402-559-5600
Languages Spoken:
English
See accepted insurances

Robert Bociek is an Oncologist in Omaha, Nebraska. Dr. Bociek is highly rated in 25 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
17
conditions
Dr. Luke Nordquist
Oncology
Expertise in
17
conditions
Dr. Luke Nordquist
Oncology

The Urology Cancer Center

17607 Gold Plz, 
Omaha, NE 
 (11.2 miles away)
402-991-8468
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Luke Nordquist is an Oncologist in Omaha, Nebraska. Dr. Nordquist is highly rated in 17 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, and Prostatectomy.

Frequently Asked Questions about Dr. Benjamin Teply

How do I make an appointment with Dr. Benjamin Teply?

You can book an appointment with Dr. Benjamin Teply by calling their office at 402-559-5600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Benjamin Teply a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Benjamin Teply is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Benjamin Teply specialize in?

While Dr. Benjamin Teply is a Oncology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and WT1-Related Wilms Tumor Syndromes. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Benjamin Teply participate in research or clinical trials?

Yes. Dr. Benjamin Teply has published 48 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Benjamin Teply's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Benjamin Teply accept my insurance?

Dr. Benjamin Teply accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 402-559-5600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Teply's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile